Baumann Kreuziger, LM. Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices. J Thromb Thrombolysis
2015; 39: 337–344.
Smith, LA, Cornelius, VR, Plummer, CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomized controlled trials. BMC Cancer
2010; 10: 337.
Harake, D, Franco, V, Henkel, J, Miller, T, Lipshultz, S. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol
2012; 8: 647–670.
Krischer, JP, Epstein, S, Cuthbertson, DD, Goorin, AM, Epstein, ML, Lipshultz, SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol
1997; 15: 1544–1552.
van Dalen, EC, van der Pal, HJH, Bakker, PJM, Caron, HN, Kremer, LCM. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer
2003; 40: 643–652.
Gharib, MI, Burnett, AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Failure
2002; 4: 235–242.
Posner, LE, Dukart, G, Goldberg, J, Bernstein, T, Cartwright, K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs
1985; 3: 123–132.
Shann, KG, Giacomuzzi, CR, Harness, L, et al. Complications relating to perfusion and extracorporeal circulation associated with the treatment of patients with congenital cardiac disease: Consensus Definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. In: 2008 Supplement to Cardiology in the Young: Databases and The Assessment of Complications associated with The Treatment of Patients with Congenital Cardiac Disease, Prepared by: The Multi-Societal Database Committee for Pediatric and Congenital Heart Disease, Jacobs JP (eds). Cardiol Young, 2008; 18 (Suppl 2): 206–214.
Cooper, DS, Pretre, R. Clinical management of pediatric ventricular assist devices. Pediatr Crit Care Med
2013; 14: S27–S36.
Jefferies, JL, Morales, DL. Mechanical circulatory support in children: bridge to transplant versus recovery. Curr Heart Fail Rep
2012; 9: 236–243.
O’Connor, MJ, Rossano, JW. Ventricular assist devices in children. Curr Opin Cardiol
2014; 29: 113–121.
Thiagarajan, RR, Almond, CS, Cooper, DS, Morales, DL. Ventricular assist devices for mechanical circulatory support in children. World J Pediatr Congenit Heart Surg
2012; 3: 104–109.
Wilmot, I, Lorts, A, Morales, D. Pediatric mechanical circulatory support. Korean J Thorac Cardiovasc Surg
2013; 46: 391–401.
Kurihara, C, Nishimura, T, Nawata, K, et al. Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy. J Artif Organs
2011; 14: 249–252.
Schweiger, M, Dave, H, Lemme, F, et al. Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child. ASAIO J
2013; 59: 520–522.
Cavigelli-Brunner, A, Schweiger, M, Knirsch, W, et al. VAD as bridge to recovery in anthracycline-induced cardiomyopathy and HHV6 myocarditis. Pediatrics
2014; 134: e894–e899.
Freilich, M, Stub, D, Esmore, D, et al. Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device. J Heart Lung Transplant
2009; 28: 101–103.
Schranz, D, Akintuerk, H, Voelkel, NF. ‘End-stage’ heart failure therapy: potential lessons from congenital heart disease: from pulmonary artery banding and interatrial communication to parallel circulation. Heart
2017; 103: 262–267.
Latus, H, Hachmann, P, Gummel, K, et al. Biventricular response to pulmonary artery banding in children with dilated cardiomyopathy. J Heart Lung Transplant
2016; 35: 934–938.